Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors-Reference-Cited by-同舟云学术

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Published:2019-03 Issue:3 Volume:26 Page:340-351.e3
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Besse Andrej,Besse Lenka,Kraus Marianne,Mendez-Lopez Max,Bader Jürgen,Xin Bo-Tao,de Bruin Gerjan,Maurits Elmer,Overkleeft Herman S.,Driessen Christoph

Funder

Krebsliga Schweiz

Wilhelm Sander-Stiftung

Onyx

Amgen

Promedica Stiftung

Swiss National Foundation

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference52 articles.

1. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir;Abt;BJU Int.,2018

2. Ixazomib: a review in relapsed and/or refractory multiple myeloma;Al-Salama;Target Oncol.,2017

3. Murine hind limb long bone dissection and bone marrow isolation;Amend;J. Vis. Exp.,2016

4. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events;Arastu-Kapur;Clin. Cancer Res.,2011

5. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation;Arendt;Proc. Natl. Acad. Sci. U S A,1997

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clickable Probes for Pathogen Proteasomes: Synthesis and Applications;ACS Omega;2024-08-02

2. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases;Signal Transduction and Targeted Therapy;2024-07-12

3. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer;British Journal of Cancer;2024-07-05

4. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma;Cancer Medicine;2024-07

5. Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors;Bioorganic & Medicinal Chemistry;2024-04